customContents

entityId

entityUuid

articlePageQuery

filter

article

articleBaseAdvertisingInfoArticle

articleListArticle

articleSeoArticle

helpersCheckIsPostiesArticle

hooksArticleAcknowledgementGateOverlayArticle

hooksTrackPageViewArticle

hooksContentInterestArticle

articleLinkingDataContent

articleSchemaContent

liveArticle

advertZone

sentiment

contentLock

topics

types

sections

moreOnThisArticles

urlAlias

commentCount

sponsorType

authorLocations

authors

paywallTypes

corrections

displaySlideShow

multimediaEmbed

printHeadline

seriesContainer

socialHeadline

headline

flag

firstTopic

glossary

flattenTypeIds

publishedDate

additionalInfoBoxes

images

image

relatedLinks

relatedNewsletters

__typename

createdDate

sponsor

factSheets

series

knowledgeQuestion

disableOffPlatformContent

published

updatedDate

summary

subHeadline

body

keywords

copyrighted

customTimezone

liveContents

Fiona Sun

Hong Kong liver cancer patients can receive a painless treatment that uses ultrasound waves to destroy cancerous tissue after the Li Ka Shing Foundation donated Asia’s first cutting-edge, non-invasive device to the city’s oldest university.
The University of Hong Kong’s Li Ka Shing Faculty of Medicine unveiled the new histotripsy treatment during a press event at Queen Mary Hospital in Pok Fu Lam on Tuesday.
The event also featured an appearance via live video link by business magnate Li Ka-shing, who waved to researchers and reporters as he hailed the new technology as “incredible”.
The non-invasive ultrasound treatment will be offered to 20 hospital patients free of charge over the next two years as part of a research programme led by the university.
The first patient is expected to start treatment this week.
“We hope that after the research programme, the treatment will be made regular and benefit more patients at public hospitals in the future,” said Professor Albert Chan Chi-yan of the university’s department of surgery.
Liver cancer is the fifth most common form of cancer in Hong Kong, with about 1,800 new cases and more than 1,500 related deaths recorded each year. More than 80 per cent of all cases were also diagnosed at a late stage.
Treatment options for liver cancer currently include surgical resection, liver transplant, ablation, radiotherapy, chemotherapy, targeted therapy and immunotherapy – all of which require patients to undergo a long recovery process.
Histotripsy is a non-invasive treatment that uses high-intensity ultrasound waves to precisely disrupt cancer tissue without damaging the surrounding healthy tissue.
The devices uses the targeted ultrasound waves to form microbubbles within the tumour.
The bubbles then rapidly expand and collapse, generating shock waves that disrupt and liquefy the targeted tumour cells.

The new device has an advanced precision treatment arm, a therapy transducer and a water bath.
The procedure, which involves no incisions or radiation, is painless and does not leave scars on patients who are not at risk of infection or metastasis – the spread of cancer cells to other parts of the body.
The treatment is considered more targeted and effective than traditional radiotherapy or surgical procedures.
Chan said the treatment also offered a speedier recovery, with patients able to be discharged on the same day as the procedure or a day later.
He added that each treatment using the new device costs US$8,000, or about HK$62,400.
The new technology was developed by the University of Michigan in 2001 and approved by the US Food and Drug Administration last year.
According to researchers, nearly 400 patients had been treated at US medical institutions using the new technology, with clinical data showing those who underwent the procedure recovered well after the operation.
They added that the patients had not suffered from any local recurrence of the targeted tumours or major complications, indicating the treatment was safe and effective.

Mike Blue, CEO of HistoSonics, the US manufacturer of the histotripsy system, said the new technology could also be used to treat other forms of cancer.
“It does not discriminate against the type of cancer. It will destroy any cancer cell,” he said.
Alongside the ultrasound device, the Li Ka Shing Foundation has also supported the training of six doctors and radiologists in using the technology by HistoSonics.
Another histotripsy system donated to the Chinese University of Hong Kong’s medical faculty is expected to arrive by the end of this year.
The foundation said it had set aside more than US$6 million as part of the donation of the two devices and patient treatment, as well as helping to cover the training of medical staff in the United States.
The organisation stopped short of revealing the exact cost of the new technology.


Foreign hospitals add to healthcare choice

Hong Kong has outbreak of deadly fish-linked infection. Here’s how you can protect yourself

How Hong Kong researchers aim to turn bugs into drugs to treat autism and dementia

Case can be made for more maternity leave

Hong Kong healthcare and hospitals

Li Ka Shing Foundation funds non-invasive liver cancer treatment for Hong Kong patients

Business magnate Li Ka-shing (centre) also made a virtual appearance at the ultrasound medical device’s unveiling on Tuesday. Photo: Xiaomei Chen

Professor Albert Chan of the university’s department of surgery says new treatment also offers a speedier recovery, with patients able to be discharged on the same day as the procedure or a day later. Photo: Xiaomei Chen

The new device can also be used to treat other forms of cancer, according to its manufacturer. Photo: Xiaomei Chen

Researchers in Switzerland carry out Hong Kong endoscope operation from 9,300km away

Researchers say they hope to start human trials for the new endoscope technology in two years. Photo: Dickson Lee

Professor Bradley Nelson, head of ETH Zurich’s Institute of Robotics and Intelligent Systems, says the breakthrough means future telesurgeries might be performed in remote regions. Photo: Dickson Lee

Researchers show how to operate the remotely controlled endoscope, which uses a magnetic navigation system. Photo: Dickson Lee

Targeted drug, radiotherapy could prolong lives of liver cancer patients with resistance to immunotherapy, Hong Kong studies find

Medical experts from the Chinese University of Hong Kong have found that a targeted drug and radiotherapy could be used to prolong the lives of liver cancer patients. Photo: Xiaomei Chen

A slideshow of organs and cancer. Forty-seven liver cancer patients were recruited for the study. Photo: Xiaomei Chen

Professor Stephen Chan says targeted therapy can be used if a patient develops resistance to immunotherapy. Photo: Xiaomei Chen

News

Hong Kong

Health & Environment

Li Ka Shing Foundation donates Asia’s first cutting-edge, non-invasive device for treatment of liver cancer to city’s oldest university


Li Ka Shing Foundation donates Asia’s first cutting-edge, non-invasive device for treatment of liver cancer to city’s oldest university.
